Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P60484
UPID:
PTEN_HUMAN
Alternative names:
Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog
Alternative UPACC:
P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7
Background:
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase, known as PTEN, plays a pivotal role in cellular processes by dephosphorylating phosphoinositides and proteins. It acts as a tumor suppressor, modulating cell cycle progression, cell survival, and migration. PTEN's involvement in the PI3K-AKT signaling pathway and its impact on mitochondrial metabolism underscore its critical biological functions.
Therapeutic significance:
PTEN's mutation or dysfunction is linked to various diseases, including Cowden syndrome, Lhermitte-Duclos disease, and several cancers such as endometrial, prostate, and glioma. Understanding PTEN's role could open doors to potential therapeutic strategies, particularly in targeting the PI3K-AKT pathway for cancer treatment and managing hamartomatous syndromes.